BA
ESPR

Bristlecone Advisors’s Esperion Therapeutics ESPR Stock Holding History

Bristlecone Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500
Closed -$25K – 182
2017
Q3 		$25K Buy
+500
New +$24.1K 0.01% 235

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bristlecone Advisors's ESPR Position: Q4 2017 in Review

Bristlecone Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 500 shares — an estimated $25K sold.

Bristlecone Advisors first reported a position in ESPR in Q3 2017 and held it in 1 quarter. The position peaked at $25K in Q3 2017. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Bristlecone Advisors reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Bristlecone Advisors sold 500 Esperion Therapeutics shares in Q4 2017, an estimated $25K.
  • Bristlecone Advisors first reported a position in Esperion Therapeutics in Q3 2017 and held it in 1 quarter.
  • Bristlecone Advisors's Esperion Therapeutics position peaked at $25K in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Bristlecone Advisors's 13F filing for Q4 2017, filed 30 Jan 2018.